These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 18778112)

  • 21. Selection, design, and engineering of therapeutic antibodies.
    Presta LG
    J Allergy Clin Immunol; 2005 Oct; 116(4):731-6; quiz 737. PubMed ID: 16210043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies: technologies for early discovery and engineering.
    Kennedy PJ; Oliveira C; Granja PL; Sarmento B
    Crit Rev Biotechnol; 2018 May; 38(3):394-408. PubMed ID: 28789584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant antibodies: alternative strategies for developing and manipulating murine-derived monoclonal antibodies.
    Peterson NC
    Lab Anim Sci; 1996 Feb; 46(1):8-14. PubMed ID: 8699826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Principles and application of antibody libraries for infectious diseases.
    Lim BN; Tye GJ; Choong YS; Ong EB; Ismail A; Lim TS
    Biotechnol Lett; 2014 Dec; 36(12):2381-92. PubMed ID: 25214212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody engineering: facing new challenges in cancer therapy.
    Sanz L; Cuesta AM; Compte M; Alvarez-Vallina L
    Acta Pharmacol Sin; 2005 Jun; 26(6):641-8. PubMed ID: 15916728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRISPR/Cas9-based Engineering of Immunoglobulin Loci in Hybridoma Cells.
    Gall CLM; Fennemann FL; Van Der Schoot JMS; Scheeren FA; Verdoes M
    Bio Protoc; 2023 Feb; 13(4):e4613. PubMed ID: 36845533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.
    Niwa R; Satoh M
    J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging trends and therapeutic applications of monoclonal antibodies.
    Mekala JR; Nalluri HP; Reddy PN; S B S; N S SK; G V S D SK; Dhiman R; Chamarthy S; Komaragiri RR; Manyam RR; Dirisala VR
    Gene; 2024 Oct; 925():148607. PubMed ID: 38797505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody engineering at the millennium.
    Gavilondo JV; Larrick JW
    Biotechniques; 2000 Jul; 29(1):128-32, 134-6, 138 passim. PubMed ID: 10907088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Production of therapeutic antibodies with controlled fucosylation.
    Yamane-Ohnuki N; Satoh M
    MAbs; 2009; 1(3):230-6. PubMed ID: 20065644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody engineering for the development of therapeutic antibodies.
    Kim SJ; Park Y; Hong HJ
    Mol Cells; 2005 Aug; 20(1):17-29. PubMed ID: 16258237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody Engineering for Pursuing a Healthier Future.
    Saeed AF; Wang R; Ling S; Wang S
    Front Microbiol; 2017; 8():495. PubMed ID: 28400756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineered antibody fragments and the rise of single domains.
    Holliger P; Hudson PJ
    Nat Biotechnol; 2005 Sep; 23(9):1126-36. PubMed ID: 16151406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal Antibodies: A Prospective and Retrospective View.
    Sivaccumar J; Sandomenico A; Vitagliano L; Ruvo M
    Curr Med Chem; 2021; 28(3):435-471. PubMed ID: 32072887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radioimmunotherapy with engineered antibodies.
    Russeva MG; Adams GP
    Expert Opin Biol Ther; 2004 Feb; 4(2):217-31. PubMed ID: 14998779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation and production of engineered antibodies.
    Kipriyanov SM; Le Gall F
    Mol Biotechnol; 2004 Jan; 26(1):39-60. PubMed ID: 14734823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Commercial development considerations for biotechnology-derived therapeutics.
    Marafino BJ; Pugsley MK
    Cardiovasc Toxicol; 2003; 3(1):5-12. PubMed ID: 12668886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality.
    Congy-Jolivet N; Probst A; Watier H; Thibault G
    Crit Rev Oncol Hematol; 2007 Dec; 64(3):226-33. PubMed ID: 17716905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selecting and screening recombinant antibody libraries.
    Hoogenboom HR
    Nat Biotechnol; 2005 Sep; 23(9):1105-16. PubMed ID: 16151404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic antibodies and other proteins obtained by molecular display technologies.
    Shibasaki S; Ueda M
    Recent Pat Biotechnol; 2009; 3(1):19-27. PubMed ID: 19149719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.